| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C16H20N2O5.Tc.H |
| Molecular Weight | 740.595 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[99Tc+3].CCC1=CC=CC(CC)=C1NC(=O)CN(CC([O-])=O)CC([O-])=O.CCC2=CC=CC(CC)=C2NC(=O)CN(CC([O-])=O)CC([O-])=O
InChI
InChIKey=UWBDZLSLZZGHFD-FCHARDOESA-K
InChI=1S/2C16H22N2O5.Tc/c2*1-3-11-6-5-7-12(4-2)16(11)17-13(19)8-18(9-14(20)21)10-15(22)23;/h2*5-7H,3-4,8-10H2,1-2H3,(H,17,19)(H,20,21)(H,22,23);/q;;+3/p-3/i;;1+1
Molybdenum-99 (99Mo, half-life = 66 h) is a parent radionuclide of a diagnostic nuclear isotope. It decays in technetium-99 m (half-life = 6 h), which is used in over 30 million procedures per year around the world. Between 95 and 98 percent of Mo-99 is currently being produced using highly enriched uranium (HEU) targets. Other medical isotopes such as iodine-131 (I-131) and xenon-133 (Xe-133) are by-products of the Mo-99 production process and will be sufficiently available if Mo-99 is available.
Approval Year
PubMed
Patents
ACTIVE MOIETY
SUBSTANCE RECORD
